How to buy Chimerix stock | 3.57

Chimerix, Inc is a biotechnology business based in the US. Chimerix shares (CMRX) are listed on the NASDAQ and all prices are listed in US Dollars. Chimerix employs 43 staff and has a trailing 12-month revenue of around USD$11.4 million.

How to buy shares in Chimerix

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Chimerix. Find the stock by name or ticker symbol: CMRX. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Chimerix reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$3.57, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Chimerix, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Chimerix. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Chimerix share price

Use our graph to track the performance of CMRX stocks over time.

Chimerix shares at a glance

• Key figures

Information last updated 2020-10-20.

Latest market close	USD$3.57
52-week range	USD$1.19 - USD$3.885
50-day moving average	USD$2.6556
200-day moving average	USD$2.7854
Wall St. target price	USD$6.67
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-1.321

Buy Chimerix shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Chimerix stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Chimerix, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Chimerix price performance over time

Historical closes compared with the close of $3.57 from 2020-11-16

1 week (2020-11-17)	4.39%
1 month (2020-10-23)	26.60%
3 months (2020-08-24)	24.83%
6 months (2020-05-22)	6.89%

1 year (2019-11-22)	69.19%
2 years (2018-11-23)	9.17%
3 years (2017-11-24)	-20.49%
5 years (2015-11-24)	-91.11%

Chimerix financials

Revenue TTM	USD$11.4 million
Gross profit TTM	USD$-25,972,000
Return on assets TTM	-16.69%
Return on equity TTM	-80.63%
Profit margin	0%
Book value	$1.498
Market capitalisation	USD$189.1 million

TTM: trailing 12 months

Shorting Chimerix shares

There are currently 895,389 Chimerix shares held short by investors – that's known as Chimerix's "short interest". This figure is 5.2% up from 851,276 last month.

There are a few different ways that this level of interest in shorting Chimerix shares can be evaluated.

Chimerix's "short interest ratio" (SIR)

Chimerix's "short interest ratio" (SIR) is the quantity of Chimerix shares currently shorted divided by the average quantity of Chimerix shares traded daily (recently around 473750.79365079). Chimerix's SIR currently stands at 1.89. In other words for every 100,000 Chimerix shares traded daily on the market, roughly 1890 shares are currently held short.

However Chimerix's short interest can also be evaluated against the total number of Chimerix shares, or, against the total number of tradable Chimerix shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Chimerix's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Chimerix shares in existence, roughly 10 shares are currently held short) or 0.0186% of the tradable shares (for every 100,000 tradable Chimerix shares, roughly 19 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Chimerix.

Find out more about how you can short Chimerix stock.

Chimerix share dividends

We're not expecting Chimerix to pay a dividend over the next 12 months.

Chimerix share price volatility

Over the last 12 months, Chimerix's shares have ranged in value from as little as $1.19 up to $3.885. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Chimerix's is 1.7871. This would suggest that Chimerix's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Chimerix overview

Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include dociparstat sodium (DSTAT), a potential first-in-class glycosaminoglycan compound derived from porcine heparin that has low anticoagulant activity but retains the ability to inhibit activities of key proteins implicated in the retention and viability of acute myeloid leukemia blasts and leukemic stem cells in the bone marrow during chemotherapy; and brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications; and University of Michigan to research, develop, manufacture, and commercialize various products. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.

Frequently asked questions

• What percentage of Chimerix is owned by insiders or institutions?

  Currently 17.96% of Chimerix shares are held by insiders and 56.314% by institutions.

• How many people work for Chimerix?

  Latest data suggests 43 work at Chimerix.

• When does the fiscal year end for Chimerix?

  Chimerix's fiscal year ends in December.

• Where is Chimerix based?

  Chimerix's address is: 2505 Meridian Parkway, Durham, NC, United States, 27713

• What is Chimerix's CUSIP number?

  Chimerix's Committee on Uniform Securities Identification Procedures number is: 16934W106